Market Cap | 25.48M | P/E | - | EPS this Y | 76.40% | Ern Qtrly Grth | - |
Income | -38.19M | Forward P/E | -6.46 | EPS next Y | 83.30% | 50D Avg Chg | 3.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | 18.00% |
Dividend | N/A | Price/Book | 0.67 | EPS next 5Y | - | 52W High Chg | -2.00% |
Recommedations | 3.00 | Quick Ratio | 11.66 | Shares Outstanding | 43.83M | 52W Low Chg | 92.00% |
Insider Own | 14.78% | ROA | -36.86% | Shares Float | 31.05M | Beta | -0.74 |
Inst Own | 37.13% | ROE | -90.72% | Shares Shorted/Prior | 87.42K/105.16K | Price | 0.58 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 55,872 | Target Price | - |
Oper. Margin | - | Earnings Date | Aug 8 | Volume | 83,889 | Change | -1.29% |
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Canaccord Genuity | Hold | Oct 22, 21 |
HC Wainwright & Co. | Neutral | Oct 22, 21 |
HC Wainwright & Co. | Buy | Jun 14, 21 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Leonard Braden Michael | 10% Owner 10% Owner | Dec 19 | Buy | 0.39 | 271,605 | 105,926 | 6,160,570 | 12/21/22 |
Leonard Braden Michael | 10% Owner 10% Owner | Nov 07 | Buy | 0.4 | 164,270 | 65,708 | 5,888,965 | 11/09/22 |
Leonard Braden Michael | 10% Owner 10% Owner | Oct 27 | Buy | 0.39 | 812,529 | 316,886 | 5,724,695 | 10/31/22 |
venBio Global Strategic Fund,... | 10% Owner 10% Owner | Oct 22 | Sell | 1.56 | 615,702 | 960,495 | 2,443,421 | 10/26/21 |